Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTT-4: Baricitinib vs Dexamethasone with Remdesivir for COVID-19
NCT04640168Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2020
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 5
01
Overview
A Phase 3 trial of baricitinib in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2020; status: completed.
02
Drugs
baricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04640168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640168.